Hypotension from afatinib in epidermal growth factor receptor-mutated non-small cell lung cancer: a case report and literature review

被引：2
|
作者：
Tang, Zhiwei [1 ]
Ji, XiuHai [2 ]
Zhou, Guanghui [1 ]
Chen, Ruhua [1 ]
Fen, Yan [1 ]
Ding, Hui [1 ]
机构：
[1] Jiangsu Univ, Affiliated Yixing Peoples Hosp, Dept Pulm & Crit Care Med, Yixing, Peoples R China
[2] Affiliated Taicang Hosp Tradit Chinese Med, Dept Oncol, Taicang, Peoples R China
来源：
ANTI-CANCER DRUGS | 2022年 / 33卷 / 01期
关键词：
afatinib; epidermal growth factor receptor; hypotension; lung cancer;
D O I：
10.1097/CAD.0000000000001244
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Side effects of afatinib are a problem in patients with advanced non-small cell lung cancer (NSCLC). However, little is known about the occurrence of afatinib-induced hypotension. An 81-year-old man with NSCLC had an epidermal growth factor receptor-positive genotype with the p.L861Q mutation in exon 21. He was administered afatinib (40 mg/day) as anticancer therapy. Hypotension occurred twice after afatinib initiation. He suffered from dizziness and nausea. Blood pressure gradually returned to normal after afatinib cessation. Clinicians should be aware of hypotension in patients with NSCLC after afatinib initiation.
引用
收藏
页码：E840 / E841
页数：2
相关论文
共 50 条
  • [41] Epidermal growth factor receptor inhibition and non-small cell lung cancer
    von Eyben, Finn Edler
    CRITICAL REVIEWS IN CLINICAL LABORATORY SCIENCES, 2006, 43 (04) : 291 - 323
  • [42] Epidermal Growth Factor Receptor Inhibitors in Non-Small Cell Lung Cancer
    Janet E. Dancey
    Drugs, 2007, 67 : 1125 - 1138
  • [43] Prognostic value of the neutrophil-to-lymphocyte ratio and primary tumor location in epidermal growth factor receptor-mutated metastatic non-small cell lung cancer
    Xie, Xueqi
    Li, Xiaolin
    Tang, Wenjie
    Chen, Jinlong
    Xie, Peng
    Li, Minghuan
    JOURNAL OF CANCER RESEARCH AND THERAPEUTICS, 2021, 17 (07) : 1618 - 1625
  • [44] Patterns of Failure in Metastatic Epidermal Growth Factor Receptor-Mutated Non-Small Cell Lung Cancer: Implications for the Role of Definitive Local Therapy to the Primary Tumor
    Guttmann, D. M.
    Doucette, A.
    Gabriel, P. E.
    Morrissette, J. J. D.
    Kucharczuk, J.
    Levin, W. P.
    Simone, C. B., II
    Alley, E.
    Ciunci, C.
    Bauml, J.
    Langer, C.
    Aggarwal, C.
    Cohen, R.
    Evans, T. L.
    Berman, A. T.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2017, 98 (01): : 248 - 249
  • [45] Cutaneous adverse events of osimertinib in diverse patient populations with epidermal growth factor receptor-mutated non-small cell lung cancer: A retrospective cohort analysis
    Alicea, Daniel S.
    Miao, Emily
    Ch'en, Peter
    Tuckman, Steven W.
    Ohri, Nitin
    Halmos, Balazs
    Cheng, Haiying
    Lee, Matthew
    Mclellan, Beth N.
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2025, 92 (03) : 630 - 632
  • [46] Risk factors of acquired T790M mutation in patients with epidermal growth factor receptor-mutated advanced non-small cell lung cancer
    Ouyang, Wen
    Yu, Jing
    Huang, Zhao
    Chen, Gang
    Liu, Yu
    Liao, Zhengkai
    Zeng, Wei
    Zhang, Junhong
    Xie, Conghua
    JOURNAL OF CANCER, 2020, 11 (08): : 2060 - 2067
  • [47] Commentary: Treatment Considerations for Patients With Epidermal Growth Factor Receptor-Mutated Non-Small Cell Lung Cancer Brain Metastases in the Era of Tyrosine Kinase Inhibitors
    Vaca, Silvia Daniela
    Connolly, Ian David
    Ho, Clement
    Neal, Joel
    Gephart, Melanie Hayden
    NEUROSURGERY, 2018, 82 (01) : E6 - E14
  • [48] Osimertinib-Centered Therapy Against Uncommon Epidermal Growth Factor Receptor-Mutated Non-Small-Cell Lung Cancer- A Mini Review
    Song, Chengyang
    Yang, Xueying
    FRONTIERS IN ONCOLOGY, 2022, 12
  • [49] CNS Antitumor Activity of Amivantamab With Osimertinib in Epidermal Growth Factor Receptor-Mutated Non-Small Cell Lung Cancer With Acquired Mesenchymal-Epithelial Transition Amplification Resistance Mechanism: A Case Report
    Al-Obeidi, Ebaa
    Kelly, Karen
    Gandara, David R.
    Riess, Jonathan W.
    JCO PRECISION ONCOLOGY, 2024, 8
  • [50] The optimal therapy strategy for epidermal growth factor receptor-mutated non-small cell lung cancer patients with brain metastasis: A real-world study from Taiwan
    Cheng, Wen-Chien
    Shen, Yi-Cheng
    Chien, Chun-Ru
    Liao, Wei-Chih
    Chen, Chia-Hung
    Hsia, Te-Chun
    Tu, Chih-Yeh
    Chen, Hung-Jen
    THORACIC CANCER, 2022, 13 (10) : 1505 - 1512
12345